Objective:To explore the mechanism of Qingjin Huatan Decoction in regulating iron metabolism by regulating inflammatory factors in the inflammatory environment of chronic obstructive pulmonary disease.Methods:The COPD...Objective:To explore the mechanism of Qingjin Huatan Decoction in regulating iron metabolism by regulating inflammatory factors in the inflammatory environment of chronic obstructive pulmonary disease.Methods:The COPD model was prepared by tracheal drops of lipopolysaccharide(LPS)combined with smoke.40 rats were randomly divided into normal group,COPD group,roxithromycin western medicine group and Qingjin Huatan Decoction traditional Chinese medicine group(n=10).Post-molding drug administration intervention,Qingjin Huatan Decoction Chinese medicine group was given 14.62 g/kg(Qingjin Huatan Decoction),roxithromycin western medicine group was given 0.01575 g/kg(roxithromycin),COPD group and normal group were given normal saline 10 mL/kg,twice a day.The expressions of Hepcidin,IL-1β,IL-10 and TGF-β1 in serum of rats in each group were detected by ELISA.WesternBlot and qRT-PCR were used to detect the expression of TF and IREB2 protein and mRNA in lung tissues of each group.Results:Compared with the normal group,the contents of serum Hepcidin and IL-10 in COPD group were significantly decreased(P<0.01),while the contents of serum IL-1βand TGF-β1 were significantly increased(P<0.01,P<0.05).Compared with COPD group,the contents of serum Hepcidin and IL-10 were significantly increased in the two drug groups(P<0.01),while the contents of serum IL-1βand TGF-β1 were significantly decreased in the two drug groups(P<0.05).Compared with normal group,TF mRNA and protein expression in COPD group were increased(P<0.01),while IREB2 mRNA and protein expression were decreased(P<0.01).Compared with COPD group,TF mRNA and protein expressions in lung tissues of the two-drug group were decreased(P<0.01,P<0.05),while IREB2 mRNA and protein expressions were increased(P<0.01).Conclusion:Iron metabolism is related to inflammation.Qingjin Huatan Decoction can regulate iron metabolism in inflammatory environment to treat COPD.展开更多
目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochran...目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochrane风险偏倚评估工具对符合纳入标准的文献进行质量评估,并利用RevMan 5.4软件进行Meta分析。结果:最终有6项临床研究符合纳入标准,总计443例患者(试验组221例,对照组222例)。清金化痰汤合麻杏石甘汤(试验组)显著提高总有效率[OR=6.64,95%CI(2.45,17.98),P<0.00001];改善咳嗽[MD=-1.09,95%CI(-1.21,-0.97),P<0.00001]、喘息[MD=-1.18,95%CI(-1.31,-1.06),P<0.00001]、哮鸣音症状[MD=-1.05,95%CI(-1.13,-0.97),P<0.00001];显著提高显著提高第1秒用力呼气量(Forced Expiratory Volume in First Second,FEV_(1))[MD=0.44,95%CI(0.34,0.53),P<0.00001]、第1秒用力呼气量占预计值的百分比(FEV_(1)%)[MD=5.48,95%CI(3.32,7.64),P<0.00001];且并未增加不良反应的发生[RR=0.79,95%CI(0.43,1.45),P=0.45]。结论:清金化痰汤合麻杏石甘汤可提高治疗慢阻肺的临床疗效,改善临床症状,且安全性高。展开更多
基金supported by National Natural Science Foundation Project(8216088,81760848)Guangxi University Young and Middle-aged Teachers Basic Ability Improvement Project(2021KY310)Guangxi Medical and Health Key Cultivation Discipline Construction Project Fund Project。
文摘Objective:To explore the mechanism of Qingjin Huatan Decoction in regulating iron metabolism by regulating inflammatory factors in the inflammatory environment of chronic obstructive pulmonary disease.Methods:The COPD model was prepared by tracheal drops of lipopolysaccharide(LPS)combined with smoke.40 rats were randomly divided into normal group,COPD group,roxithromycin western medicine group and Qingjin Huatan Decoction traditional Chinese medicine group(n=10).Post-molding drug administration intervention,Qingjin Huatan Decoction Chinese medicine group was given 14.62 g/kg(Qingjin Huatan Decoction),roxithromycin western medicine group was given 0.01575 g/kg(roxithromycin),COPD group and normal group were given normal saline 10 mL/kg,twice a day.The expressions of Hepcidin,IL-1β,IL-10 and TGF-β1 in serum of rats in each group were detected by ELISA.WesternBlot and qRT-PCR were used to detect the expression of TF and IREB2 protein and mRNA in lung tissues of each group.Results:Compared with the normal group,the contents of serum Hepcidin and IL-10 in COPD group were significantly decreased(P<0.01),while the contents of serum IL-1βand TGF-β1 were significantly increased(P<0.01,P<0.05).Compared with COPD group,the contents of serum Hepcidin and IL-10 were significantly increased in the two drug groups(P<0.01),while the contents of serum IL-1βand TGF-β1 were significantly decreased in the two drug groups(P<0.05).Compared with normal group,TF mRNA and protein expression in COPD group were increased(P<0.01),while IREB2 mRNA and protein expression were decreased(P<0.01).Compared with COPD group,TF mRNA and protein expressions in lung tissues of the two-drug group were decreased(P<0.01,P<0.05),while IREB2 mRNA and protein expressions were increased(P<0.01).Conclusion:Iron metabolism is related to inflammation.Qingjin Huatan Decoction can regulate iron metabolism in inflammatory environment to treat COPD.
文摘目的 探讨加减清金化痰汤联合头孢唑肟治疗进展期非小细胞肺癌(non-small-cell lung cancer, NSCLC)化疗后肺部感染的效果及对血清中性粒细胞与淋巴细胞比值(Neutrophils lymphocytes ratio, NLR)、降钙素原(Procalcitonin, PCT)、高迁移率族蛋白B1(High mobility group box 1,HMGB1)水平、免疫状态的影响。方法 选取2018年3月—2021年3月我院进展期NSCLC化疗后肺部感染患者102例,以随机数字表法分为治疗组、对照组,各51例。对照组给予头孢唑肟治疗,治疗组在对照组基础上给予加减清金化痰汤治疗,均治疗2 w。比较两组肺部感染疗效、感染症状改善情况、不良反应以及治疗前、治疗2 w后血清血清中性粒细胞与淋巴细胞比值(Neutrophil to Lymphocyte Ratio, NLR)、降钙素原(Procalcitonin, PCT)、高迁移率族蛋白B1(High mobility group box 1,HMGB1)、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肺功能指标[用力肺活量(Forced vital capacity, FVC)、每分钟最大通气量占预计值百分比(Maximum ventilation volume per minute as a percentage of expected value, MVV)、第1 s用力呼气容积占预计值百分比(percentage of forced expiratory volume in first second to predicted value, FEV1)]水平。结果 治疗组治疗2 w后总有效率为92.16%,高于对照组的76.47%(P<0.05);经治疗,治疗组退热、咳嗽消失、肺部啰音消失时间较对照组短(P<0.05);治疗组治疗2 w后血清NLR、PCT、HMGB1、CD8^(+)水平均低于对照组,血清CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组(P<0.05);治疗组治疗2 w后FVC、MVV、FEV1水平均高于对照组(P<0.05);两组治疗期间不良反应发生率相比,差异无统计学意义(P>0.05)。结论 应用加减清金化痰汤联合头孢唑肟治疗进展期NSCLC化疗后肺部感染可减轻感染症状,降低血清NLR、PCT、HMGB1表达,提升免疫功能与肺功能,安全有效。
文摘目的:通过Meta分析清金化痰汤合麻杏石甘汤治疗慢性阻塞性肺疾病(简称慢阻肺)的疗效及安全性。方法:利用PubMed数据库、中国知网等数据库,检索自建库至2022年10月有关清金化痰汤合麻杏石甘汤治疗慢阻肺的临床随机对照试验。依据Cochrane风险偏倚评估工具对符合纳入标准的文献进行质量评估,并利用RevMan 5.4软件进行Meta分析。结果:最终有6项临床研究符合纳入标准,总计443例患者(试验组221例,对照组222例)。清金化痰汤合麻杏石甘汤(试验组)显著提高总有效率[OR=6.64,95%CI(2.45,17.98),P<0.00001];改善咳嗽[MD=-1.09,95%CI(-1.21,-0.97),P<0.00001]、喘息[MD=-1.18,95%CI(-1.31,-1.06),P<0.00001]、哮鸣音症状[MD=-1.05,95%CI(-1.13,-0.97),P<0.00001];显著提高显著提高第1秒用力呼气量(Forced Expiratory Volume in First Second,FEV_(1))[MD=0.44,95%CI(0.34,0.53),P<0.00001]、第1秒用力呼气量占预计值的百分比(FEV_(1)%)[MD=5.48,95%CI(3.32,7.64),P<0.00001];且并未增加不良反应的发生[RR=0.79,95%CI(0.43,1.45),P=0.45]。结论:清金化痰汤合麻杏石甘汤可提高治疗慢阻肺的临床疗效,改善临床症状,且安全性高。
